Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1,…
Brook StarRay Wireless Controller Now Available — Native PS5 Support Meets Xbox-Style Control
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight
Scalare Launches EquityRoom, Adding a Subscription Revenue Stream to Its Founder Ecosystem
Megaannum Capital and Zhongke Xianxing Venture Capital Enter into Strategic Partnership